Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Hansa Biopharma price target raised to SEK 323 from SEK 287 at RBC Capital » 12:40
06/01/21
06/01
12:40
06/01/21
12:40
HNSBF

Hansa Biopharma

$16.40 /

+ (+0.00%)

RBC Capital analyst Zoe…

RBC Capital analyst Zoe Karamanoli raised the firm's price target on Hansa Biopharma to SEK 323 from SEK 287 and keeps an Outperform rating on the shares.

ShowHide Related Items >><<
HNSBF Hansa Biopharma
$16.40 /

+ (+0.00%)

04/26/21 Danske Bank
Hansa Biopharma initiated with a Buy at Danske Bank
07/07/20 RBC Capital
Hansa Biopharma upgraded to Outperform from Sector Perform at RBC Capital
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
Over a month ago
Conference/Events
Hansa Biopharma management to meet virtually with Truist » 10:24
05/14/21
05/14
10:24
05/14/21
10:24
HNSBF

Hansa Biopharma

$16.99 /

+ (+0.00%)

Virtual Meeting to be…

Virtual Meeting to be held on May 14 hosted by Truist.

ShowHide Related Items >><<
HNSBF Hansa Biopharma
$16.99 /

+ (+0.00%)

04/26/21 Danske Bank
Hansa Biopharma initiated with a Buy at Danske Bank
07/07/20 RBC Capital
Hansa Biopharma upgraded to Outperform from Sector Perform at RBC Capital
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
Conference/Events
Hansa Biopharma management to meet virtually with Truist » 04:55
05/07/21
05/07
04:55
05/07/21
04:55
HNSBF

Hansa Biopharma

$16.99 /

+ (+0.00%)

Virtual Meeting to be…

Virtual Meeting to be held on May 7 hosted by Truist.

ShowHide Related Items >><<
HNSBF Hansa Biopharma
$16.99 /

+ (+0.00%)

04/26/21 Danske Bank
Hansa Biopharma initiated with a Buy at Danske Bank
07/07/20 RBC Capital
Hansa Biopharma upgraded to Outperform from Sector Perform at RBC Capital
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
Conference/Events
Hansa Biopharma management to meet virtually with Truist » 10:18
05/06/21
05/06
10:18
05/06/21
10:18
HNSBF

Hansa Biopharma

$16.99 /

+ (+0.00%)

Virtual Meeting to be…

Virtual Meeting to be held on May 7 hosted by Truist.

ShowHide Related Items >><<
HNSBF Hansa Biopharma
$16.99 /

+ (+0.00%)

04/26/21 Danske Bank
Hansa Biopharma initiated with a Buy at Danske Bank
07/07/20 RBC Capital
Hansa Biopharma upgraded to Outperform from Sector Perform at RBC Capital
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
Initiation
Hansa Biopharma initiated with a Buy at Danske Bank » 05:12
04/26/21
04/26
05:12
04/26/21
05:12
HNSBF

Hansa Biopharma

$16.99 /

+ (+0.00%)

Danske Bank initiated…

Danske Bank initiated coverage of Hansa Biopharma with a Buy rating and SEK 305 price target.

ShowHide Related Items >><<
HNSBF Hansa Biopharma
$16.99 /

+ (+0.00%)

07/07/20 RBC Capital
Hansa Biopharma upgraded to Outperform from Sector Perform at RBC Capital
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
Over a quarter ago
Conference/Events
Hansa Biopharma management to meet virtually with JPMorgan » 04:55
11/03/20
11/03
04:55
11/03/20
04:55
HNSBF

Hansa Biopharma

$0.00 /

+ (+0.00%)

Virtual Meeting to be…

Virtual Meeting to be held on November 3 hosted by JPMorgan.

ShowHide Related Items >><<
HNSBF Hansa Biopharma
$0.00 /

+ (+0.00%)

07/07/20 RBC Capital
Hansa Biopharma upgraded to Outperform from Sector Perform at RBC Capital
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
Conference/Events
Hansa Biopharma management to meet virtually with JPMorgan » 09:25
10/30/20
10/30
09:25
10/30/20
09:25
HNSBF

Hansa Biopharma

$0.00 /

+ (+0.00%)

Virtual Meeting to be…

Virtual Meeting to be held on November 3 hosted by JPMorgan.

ShowHide Related Items >><<
HNSBF Hansa Biopharma
$0.00 /

+ (+0.00%)

07/07/20 RBC Capital
Hansa Biopharma upgraded to Outperform from Sector Perform at RBC Capital
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
Upgrade
Hansa Biopharma upgraded to Outperform from Sector Perform at RBC Capital » 05:40
07/07/20
07/07
05:40
07/07/20
05:40
HNSBF

Hansa Biopharma

$0.00 /

+ (+0.00%)

RBC Capital analyst Zoe…

RBC Capital analyst Zoe Karamanoli upgraded Hansa Biopharma to Outperform from Sector Perform with a SEK 270 price target.

ShowHide Related Items >><<
HNSBF Hansa Biopharma
$0.00 /

+ (+0.00%)

07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
Recommendations
Sarepta's recent deals may expand eligible patient set, says William Blair » 11:50
07/02/20
07/02
11:50
07/02/20
11:50
SRPT

Sarepta

$164.00 /

-1.585 (-0.96%)

, HNSBF

Hansa Biopharma

$0.00 /

+ (+0.00%)

William Blair analyst Tim…

William Blair analyst Tim Lugo noted that Sarepta Therapeutics (SRPT) announced an agreement with Hansa Biopharma (HNSBF) for a worldwide license to develop and promote the latter's imlifidase as a pre-treatment to enable gene therapy administration in DMD and LGMD for patients who otherwise may not be eligible for treatment due to preexisting immunity. Hansa's technology may expand the number of patients who could benefit from treatment with Sarepta's gene therapy assets, said Lugo, who noted that this is the company's third deal in as many weeks for a technology that may help overcome issues with preexisting immunity and enable treatment of a broader set of patients. Lugo has an Outperform rating on Sarepta shares.

ShowHide Related Items >><<
SRPT Sarepta
$164.00 /

-1.585 (-0.96%)

SRPT Sarepta
$164.00 /

-1.585 (-0.96%)

06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
06/08/20 Goldman Sachs
Sarepta's gene therapy program updates 'highly encouraging,' says Goldman Sachs
HNSBF Hansa Biopharma
$0.00 /

+ (+0.00%)

SRPT Sarepta
$164.00 /

-1.585 (-0.96%)

SRPT Sarepta
$164.00 /

-1.585 (-0.96%)

SRPT Sarepta
$164.00 /

-1.585 (-0.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.